学术探索
学术期刊
新闻热点
数据分析
智能评审

Prevention of end-stage renal disease due to type 2 diabetes.

被引：118
作者：
Hostetter, TH [1 ]
机构：
[1] NIDDKD, Bethesda, MD 20892 USA
来源：
NEW ENGLAND JOURNAL OF MEDICINE | 2001年 / 345卷 / 12期
关键词：
D O I：
10.1056/NEJM200109203451209
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：910 / 912
页数：3
相关论文
共 16 条
  • [1] Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis - A randomized controlled trial
    Agodoa, LY
    Appel, L
    Bakris, GL
    Beck, G
    Bourgoignie, J
    Briggs, JP
    Charleston, J
    Cheek, D
    Cleveland, W
    Douglas, JG
    Douglas, M
    Dowie, D
    Faulkner, M
    Gabriel, A
    Gassman, J
    Greene, T
    Hall, Y
    Hebert, L
    Hiremath, L
    Jamerson, K
    Johnson, CJ
    Kopple, J
    Kusek, J
    Lash, J
    Lea, J
    Lewis, JB
    Lipkowitz, M
    Massry, S
    Middleton, J
    Miller, ER
    Norris, K
    O'Connor, D
    Ojo, A
    Phillips, RA
    Pogue, V
    Rahman, M
    Randall, OS
    Rostand, S
    Schulman, G
    Smith, W
    Thornley-Brown, D
    Tisher, CC
    Toto, RD
    Wright, JT
    Xu, SC
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 285 (21): : 2719 - 2728
  • [2] Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy
    Brenner, BM
    Cooper, ME
    de Zeeuw, D
    Keane, WF
    Mitch, WE
    Parving, HH
    Remuzzi, G
    Snapinn, SM
    Zhang, ZX
    Shahinfar, S
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (12) : 861 - 869
  • [3] Should all patients with type 1 diabetes mellitus and microalbuminuria receive angiotensin-converting enzyme inhibitors? A meta-analysis of individual patient data
    Chaturvedi, N
    [J]. ANNALS OF INTERNAL MEDICINE, 2001, 134 (05) : 370 - 379
  • [4] Lesser response to angiotensin-converting-enzyme inhibitor therapy in black as compared with white patients with left ventricular dysfunction.
    Exner, DV
    Dries, DL
    Domanski, MJ
    Cohn, JN
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (18) : 1351 - 1357
  • [5] Gerstein HC, 2000, LANCET, V355, P253
  • [6] The cost-effectiveness of treating all patients with type 2 diabetes with angiotensin-converting enzyme inhibitors
    Golan, L
    Birkmeyer, JD
    Welch, HG
    [J]. ANNALS OF INTERNAL MEDICINE, 1999, 131 (09) : 660 - +
  • [7] *HEART OUTC PREV E, 2000, LANCET, V356, P860
  • [8] Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease - A meta-analysis of patient-level data
    Jafar, TH
    Schmid, CH
    Landa, M
    Giatras, I
    Toto, R
    Remuzzi, G
    Maschio, G
    Brenner, BM
    Kamper, A
    Zucchelli, P
    Becker, G
    Himmelmann, A
    Bannister, K
    Landais, P
    Shahinfar, S
    de Jong, PE
    de Zeeuw, D
    Lau, J
    Levey, AS
    [J]. ANNALS OF INTERNAL MEDICINE, 2001, 135 (02) : 73 - 87
  • [9] Long-term comparison of losartan and enalapril on kidney function in hypertensive type 2 diabetics with early nephropathy
    Lacourcière, Y
    Bélanger, A
    Godin, C
    Hallé, JP
    Ross, S
    Wright, N
    Marion, J
    [J]. KIDNEY INTERNATIONAL, 2000, 58 (02) : 762 - 769
  • [10] Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes
    Lewis, EJ
    Hunsicker, LG
    Clarke, WR
    Berl, T
    Pohl, MA
    Lewis, JB
    Ritz, E
    Atkins, RC
    Rohde, R
    Raz, I
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (12) : 851 - 860
12